



Effective Date ..... 4/18/2023  
 Next Review Date ..... 4/18/2024

## Drug Quantity Management – Per Rx Oncology – Jaypirca™ (pirtobrutinib tablets)

Table of Contents	Product Identifier(s)
National Formulary Medical Necessity ..... 1	135897
Conditions Not Covered.....2	
Background.....2	
References .....2	
Revision History.....2	

**INSTRUCTIONS FOR USE**

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

### National Formulary Medical Necessity

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Jaypirca. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for 1 year in duration.

**Drug Quantity Limit**

Product	Strength and Form	Retail Maximum Quantity per Rx	Home Delivery Maximum Quantity per Rx
Jaypirca™ (pirtobrutinib tablets)	50 mg tablets	30 tablets	90 tablets
	100 mg tablets	60 tablets	180 tablets

**Cigna covers quantities as medically necessary when the following criteria are met:**

Jaypirca 50 mg tablets

1. If the individual is taking a moderate or strong cytochrome P450 (CYP)3A inducer, approve 90 tablets per dispensing at retail or 270 tablets per dispensing at home delivery.

Note: CYP3A inducers include, but are not limited to, rifampin, carbamazepine, rifabutin, ritonavir, and St. John's Wort.

#### Jaypirca 100 mg tablets

1. If the individual is taking a moderate or strong CYP3A inducer, approve 90 tablets per dispensing at retail or 270 tablets per dispensing at home delivery.

Note: CYP3A inducers include, but are not limited to, rifampin, carbamazepine, rifabutin, ritonavir, and St. John's Wort.

## Conditions Not Covered

Any other exception is considered not medically necessary.

## Background

### Overview

#### Indication

Jaypirca, a Bruton tyrosine kinase (BTK) inhibitor, is indicated for the treatment of relapsed or refractory **mantle cell lymphoma** in adults after at least two lines of systemic therapy, including a BTK inhibitor.<sup>1</sup>

#### Dosing

The recommended dose of Jaypirca is 200 mg once daily (QD) continued until disease progression or unacceptable toxicity.<sup>1</sup> Tablets should be swallowed whole and cannot be cut, crushed, or chewed. Dose reductions may be necessary to manage adverse events. Additionally, the dose of Jaypirca should be reduced to 100 mg QD (if the current dose of 200 mg QD), otherwise reduce the dose by 50 mg, if the patient has severe renal impairment (estimated glomerular filtration rate [eGFR] 15 to 29 mL/min). If the current dose is 50 mg QD, discontinue Jaypirca.

#### Drug Interactions

Use of Jaypirca should be avoided with strong cytochrome P450 (CYP)3A inhibitors, but if use cannot be avoided, reduce the Jaypirca dose by 50 mg.<sup>1</sup> If the current daily dose is 50 mg, then interrupt Jaypirca treatment while the patient is receiving the strong CYP3A inhibitor.

Similarly, use of Jaypirca with a moderate or strong CYP3A inducer should be avoided when possible.<sup>1</sup> However, if concomitant administration is necessary, increase the dose of Jaypirca to 300 mg QD (if the current dose is 200 mg QD) or increase the current daily dose by 50 mg (if the current dose is 50 or 100 mg QD).

#### Availability

Jaypirca is supplied as 50 mg (bottles of 30 tablets) and 100 mg tablets (bottles of 60 tablets).<sup>1</sup>

## References

1. Jaypirca™ tablets [prescribing information]. Indianapolis, IN: Eli Lilly; January 2023.

## Revision History

Type of Revision	Summary of Changes	Approval Date
New Policy	--	02/08/2023

"Cigna Companies" refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc. and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2023 Cigna.